Keratoderma-Like T-Cell Dyscrasia: A Case Report.

Case Rep Dermatol

Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Published: October 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Cutaneous T-cell dyscrasia (CTCD) encompasses a heterogeneous group of T-cell infiltrates, often clonal and epitheliotropic. While the etiology remains unclear, certain medications, including statins, have been linked to cutaneous T-cell lymphocytic infiltrate development.

Case Description: A patient presented with a pruritic, scaly eruption on her palms and soles unresponsive to topical steroids for 1 month. Histopathological examination revealed compact orthokeratosis, mild lymphocytic infiltrate with focal exocytosis, and atypical lymphocytes. Immunophenotyping demonstrated a predominance of CD3+ T cells with a 1:1 CD4/CD8 ratio and reduced CD7 expression. The clinical presentation, histopathology, and immunophenotype supported a diagnosis of statin-induced CTCD.

Conclusion: Statin discontinuation led to complete symptom resolution, emphasizing the reversibility of drug-induced T-cell dyscrasia. This case highlights the importance of a detailed medication history as drug-induced T-cell dyscrasia, unlike classic CTCD with its characteristic lymphoid atypia, phenotypic abnormalities, and clonality leading to a refractory course, can be reversed by drug withdrawal.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509488PMC
http://dx.doi.org/10.1159/000541258DOI Listing

Publication Analysis

Top Keywords

t-cell dyscrasia
16
dyscrasia case
8
cutaneous t-cell
8
lymphocytic infiltrate
8
drug-induced t-cell
8
t-cell
5
keratoderma-like t-cell
4
dyscrasia
4
case report
4
report introduction
4

Similar Publications

Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception.

Best Pract Res Clin Haematol

September 2025

Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Electronic address:

Precursor plasma cell disorders include monoclonal gammopathy of undermined significance (MGUS) and smoldering multiple myeloma (SMM). These conditions carry a variable risk of progression to symptomatic myeloma and there are ongoing efforts to improve risk stratification to identify patients that are at highest risk of progression. Advanced imaging plays a crucial role in diagnosis and monitoring, and more sensitive tools to measure serum monoclonal proteins and circulating tumor cells are being developed.

View Article and Find Full Text PDF

Light-chain (AL) amyloidosis is a rare clonal plasma cell disorder that, if left untreated, carries a high risk of organ damage and mortality. Due to the rarity of the disease and the vulnerability of affected organ systems, treatment requires significant caution and nuance. As a plasma cell dyscrasia, AL amyloidosis treatment regimens are often adapted from those used for related disorders, particularly multiple myeloma.

View Article and Find Full Text PDF

The association between autoimmune diseases and lymphoproliferative disorders is well established. It is also recognized that the skin and deep subcutaneous tissue can be affected by lymphocytic infiltrates in autoimmune diseases, a hallmark of lupus erythematosus profundus or lupus panniculitis (LP). To present an unusual lymphoproliferative disorder in a patient with undifferentiated connective tissue disease (UCTD).

View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) cellular therapies have advanced outcomes in challenging hematologic malignancies like leukemia, lymphoma, and multiple myeloma. Plasma cell-directed CAR T-cell therapies have been particularly beneficial in multiple myeloma, suggesting that these agents may have a role in other challenging plasma cell disorders such as systemic AL amyloidosis and plasma cell leukemia. AL amyloidosis is a monoclonal plasma cell disorder resulting in the deposition of protein fibrils that compromise end-organ function.

View Article and Find Full Text PDF